eTable 1 Baseline characteristics and outcomes of subjects included versus the remaining in the subanalysis of the Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events (CHANCE) trial.

|  |  |  |  |
| --- | --- | --- | --- |
|  | Patients included (n=797) | Patients not included (n=4373) | P value |
| Age, mean (SD), y | 63.1 (10.8) | 62.5 (10.7) | 0.15 |
| Male, n (%) | 518 (65.0) | 2902 (66.4) | 0.46 |
| BMI, mean (SD) | 24.5 (3.3) | 24.7 (3.0) | 0.08 |
| Medical history, n (%) |  |  |  |
| Ischemic stroke | 139 (17.4) | 894 (20.4) | 0.05 |
| TIA | 28 (3.5) | 146 (3.3) | 0.83 |
| Congestive heart failure  | 16 (2.0) | 64 (1.5) | 0.27 |
| Myocardial infarction  | 14 (1.8) | 82 (1.9) | 1.0 |
| Known atrial fibrillation or flutter | 18 (2.3) | 78 (1.8) | 0.39 |
| Hypertension | 518 (65.0) | 2881 (65.9) | 0.63 |
| Diabetes mellitus | 156 (19.6) | 937 (21.4) | 0.26 |
| Hypercholesterolemia | 105 (13.2) | 468 (10.7) | 0.04 |
|  Previous or current smoker, (n%) | 340 (42.7) | 1881 (43.0) | 0.88 |
| Time to randomization, hours |  |  |  |
| <12 | 414 (51.9) | 2159 (49.4) | 0.19 |
| >12 | 383 (48.1) | 2214 (50.6) |
| Index event, n (%) |  |  |  |
| Ischemic stroke | 598 (75.0) | 3127 (71.5) | 0.05 |
| TIA | 199 (25.0) | 1246 (28.5) |
| Treatment group |  |  |  |
| Asprin | 401 (50.3) | 2185 (50.0) | 0.88 |
| Asprin/clopidogrel | 396 (49.7) | 2188 (50.0) |
| Medication during follow-up |  |  |  |
| Antihypertensive agents | 353 (44.5) | 1461 (33.7) | <0.01 |
| Hypoglycemic agents | 107 (13.5) | 549 (12.7) | 0.52 |
| Lipid-lowering agents | 417 (52.5) | 1754 (40.4) | <0.01 |
| Outcomes, n (%) |  |  |  |
| Stroke | 71 (8.9) | 444 (10.2) | 0.30 |
| Combined vascular eventsa | 73 (9.2) | 450 (10.3) | 0.37 |
| Bleeding | 17 (2.1) | 84 (1.9) | 0.68 |

Abbreviations: BMI, body mass index; TIA, transient ischemic attack; IQR, interquartile range.

a Combined vascular events referred to ischemic stroke, hemorrhagic stroke, myocardial infarction, and vascular death.

eTable 2 Baseline characteristics and clinical outcomes of patients stratified according to levels of Lp-PLA2 activity levels and presence of intracranial arterial stenosis (ICAS).

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Total patients, n=797 | With ICAS, n=356 | Without ICAS, n=441 | P value |
| Age, mean (SD), y | 63.1 (10.8) | 65.1 (10.6) | 61.5 (10.8) | <0.01 |
| Male, n (%) | 518 (65.0) | 221 (62.1) | 297 (67.4) | 0.14 |
| BMI, mean (SD) | 24.5 (3.3) | 24.5 (3.4) | 24.4 (3.2) | 0.54 |
| Medical history, n (%) |  |  |  |  |
| Ischemic stroke | 139 (17.4) | 77 (21.6) | 62 (14.1) | <0.01 |
| TIA | 28 (3.5) | 18 (5.1) | 10 (2.3) | 0.05 |
| Congestive heart failure  | 16 (2.0) | 9 (2.5) | 7 (1.6) | 0.45 |
| Myocardial infarction  | 14 (1.8) | 10 (2.8) | 4 (0.9) | 0.06 |
| Known atrial fibrillation or flutter | 18 (2.3) | 8 (2.3) | 10 (2.3) | 1.0 |
| Hypertension | 518 (65.0) | 113 (31.7) | 275 (62.4) | 0.09 |
| Diabetes mellitus | 156 (19.6) | 87 (24.4) | 69 (15.7) | <0.01 |
| Hypercholesterolemia | 105 (13.2) | 45 (12.6) | 60 (13.6) | 0.75 |
|  Previous or current smoker, (n%) | 340 (42.7) | 147 (41.3) | 193 (43.8) | 0.52 |
| Time to randomization, hours |  |  |  |  |
| <12 | 414 (51.9) | 191 (53.7) | 223 (50.6) | 0.39 |
| >12 | 383 (48.1) | 165 (46.4) | 218 (49.4) |
| Index event, n (%) |  |  |  |  |
| Ischemic stroke | 598 (75.0) | 272 (76.4) | 326 (73.9) | 0.46 |
| TIA | 199 (25.0) | 84 (23.6) | 115 (26.1) |
| Treatment group |  |  |  |  |
| Asprin | 401 (50.3) | 184 (51.7) | 217 (49.2) | 0.52 |
| Asprin/clopidogrel | 396 (49.7) | 172 (48.3) | 224 (50.8) |
| LDL-C, mean (SD), mmol/L | 3.24 (1.06) | 3.39 (1.12) | 3.12 (0.99) | <0.01 |
| Lp-PLA2, mean (SD), nmol/min/mL | 212.2 (101.9) | 220.2 (122.2) | 205.8 (81.5) | <0.01 |
| Lp-PLA2<225 nmol/min/mL | 485 (60.9) | 200 (56.2) | 285 (64.6) | 0.02 |
| Lp-PLA2 ≥225 nmol/min/mL | 312 (39.1) | 156 (43.8) | 156 (35.4) |
| Medication during follow-up |  |  |  |  |
| Antihypertensive agents | 353 (44.5) | 171 (48.0) | 182 (41.6) | 0.07 |
| Hypoglycemic agents | 107 (13.5) | 53 (14.9) | 54 (12.3) | 0.30 |
| Lipid-lowering agents | 417 (52.5) | 192 (53.9) | 225 (51.4) | 0.48 |
| Outcomes, n (%) |  |  |  |  |
| Stroke | 71 (8.9) | 44 (12.4) | 27 (6.1) | <0.01 |
| Combined vascular eventsa | 73 (9.2) | 44 (12.4) | 29 (6.6) | <0.01 |
| Bleeding | 17 (2.1) | 7 (2.0) | 10 (2.3) | 0.81 |

Abbreviations: BMI, body mass index; TIA, transient ischemic attack; IQR, interquartile range; LDL-C, low-density lipoprotein

cholesterol; hs-CRP, high-sensitive C-reactive protein

a Combined vascular events referred to ischemic stroke, hemorrhagic stroke, myocardial infarction, and vascular death.